Banque Pictet & Cie SA Sells 6,618 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Banque Pictet & Cie SA reduced its Thermo Fisher stake by 26.1% in the third quarter, selling 6,618 shares and retaining 18,703 shares valued at approximately $12.6 million. Institutional investors collectively own 89.23% of the company.
• Wall Street remains broadly positive, with Thermo Fisher holding a consensus “Moderate Buy” rating and an average price target of $654.05, although the stock’s premium valuation and recent 52-week high have prompted some caution.
• The company’s outlook is supported by strong recent earnings, recovery in its Life Sciences Solutions business and demand from research markets; analysts expect roughly $6.40 in third-quarter adjusted EPS.

Banque Pictet & Cie SA cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 26.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,703 shares of the medical research company's stock after selling 6,618 shares during the period. Banque Pictet & Cie SA's holdings in Thermo Fisher Scientific were worth $12,625,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Polaris Financial Partners bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $32,000. Kilter Group LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Legacy Wealth Managment LLC ID increased its stake in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after buying an additional 22 shares during the period. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $26,000. Finally, MBM Wealth Consultants LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $29,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Analysts expect third-quarter adjusted earnings of approximately $6.40 per share, with results likely to show whether Thermo Fisher’s growth is continuing into the second half of 2026. Thermo Fisher Scientific Q3 2026 Preview
• Positive Sentiment: Recent investor commentary cites strong operating results and a recovery in Thermo Fisher’s Life Sciences Solutions business, while academic and government research spending remain important sources of demand. Thermo Fisher Scientific Outperforms on Strong Results and Life Sciences Recovery Academic and Government Spending Powers Thermo Fisher
• Positive Sentiment: Thermo Fisher is positioned to benefit from growth in immuno-oncology diagnostics, a market forecast to reach $11.1 billion by 2030, although the opportunity is shared with competitors including Roche, Illumina and Agilent. Immuno-Oncology Diagnostics Market Forecast
• Neutral Sentiment: Analysts are also examining key metrics such as segment performance and margins for the September quarter; those details could determine whether the expected earnings growth is high quality. Analyst Projections for Thermo Fisher Key Metrics
• Negative Sentiment: Valuation concerns may be weighing on the shares. Thermo Fisher trades at a premium earnings multiple after a substantial advance and has reached a new 52-week high, prompting some analysts to maintain a cautious or “hold” view despite strong growth prospects. Thermo Fisher Strong Growth, Even Higher Stock Price

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Piper Sandler began coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an "overweight" rating for the company. TD Cowen boosted their price objective on Thermo Fisher Scientific from $675.00 to $760.00 and gave the stock a "buy" rating in a research note on Tuesday. UBS Group raised Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $540.00 to $730.00 in a research note on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a report on Friday, September 25th. Finally, Guggenheim began coverage on shares of Thermo Fisher Scientific in a research report on Thursday. They issued a "buy" rating on the stock. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $654.05.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $690.22 on Friday. The firm's 50 day moving average price is $637.32 and its two-hundred day moving average price is $548.10. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $704.00. The stock has a market cap of $255.21 billion, a PE ratio of 29.23, a PEG ratio of 2.91 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business's quarterly revenue was up 10.5% compared to the same quarter last year. During the same period last year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. Corporate insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.